- Home
- LDWY vs BGLC Comparison
LDWY vs BGLC Comparison
Compare LDWY & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- BGLC
- Stock Information
- Founded
- LDWY 1990
- BGLC 2017
- Country
- LDWY United States
- BGLC Malaysia
- Employees
- LDWY N/A
- BGLC N/A
- Industry
- LDWY Advertising
- BGLC Medical Specialities
- Sector
- LDWY Consumer Discretionary
- BGLC Health Care
- Exchange
- LDWY Nasdaq
- BGLC Nasdaq
- Market Cap
- LDWY 7.7M
- BGLC 7.6M
- IPO Year
- LDWY 1991
- BGLC N/A
- Fundamental
- Price
- LDWY $4.46
- BGLC $0.26
- Analyst Decision
- LDWY
- BGLC
- Analyst Count
- LDWY 0
- BGLC 0
- Target Price
- LDWY N/A
- BGLC N/A
- AVG Volume (30 Days)
- LDWY 13.3K
- BGLC 1.5M
- Earning Date
- LDWY 11-19-2024
- BGLC 11-15-2024
- Dividend Yield
- LDWY N/A
- BGLC N/A
- EPS Growth
- LDWY N/A
- BGLC N/A
- EPS
- LDWY N/A
- BGLC N/A
- Revenue
- LDWY $31,581,000.00
- BGLC $9,259,858.00
- Revenue This Year
- LDWY N/A
- BGLC N/A
- Revenue Next Year
- LDWY N/A
- BGLC N/A
- P/E Ratio
- LDWY N/A
- BGLC N/A
- Revenue Growth
- LDWY N/A
- BGLC N/A
- 52 Week Low
- LDWY $3.02
- BGLC $0.23
- 52 Week High
- LDWY $6.88
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- LDWY 58.14
- BGLC 40.08
- Support Level
- LDWY $4.14
- BGLC $0.25
- Resistance Level
- LDWY $4.48
- BGLC $0.28
- Average True Range (ATR)
- LDWY 0.26
- BGLC 0.05
- MACD
- LDWY -0.03
- BGLC 0.00
- Stochastic Oscillator
- LDWY 44.30
- BGLC 10.75
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two Industry Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.